Skip to main content
. 2022 Mar 16;10:e12969. doi: 10.7717/peerj.12969

Figure 4. The relationship between Cx43 and PI3K/Akt/mTOR.

Figure 4

(A–D) Immunoblot analysis of p62 (B), Beclin 1 (C) and LC3B (D) in VSMCs treated with ox-LDL after LY294002 pretreatment. (E–H) Immunoblot analysis of the marker proteins of PI3K/AKT/mTOR signaling pathway in VSMCs after Gap pretreatment. (I and J) Immunoblot analysis of Cx43 in ox-LDL-treated VSMCs after LY294002 pretreatment. (*P < 0.05 vs. Control, **P < 0.01 vs. Control, #P < 0.05 vs. ox-LDL, n = 3, data shown as the mean ± SD).